[{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"022a29da-b197-4827-a622-2e8a2fce79e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491955","created_at":"2021-01-18T21:34:47.909Z","updated_at":"2024-07-02T16:35:29.342Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","source_id_and_acronym":"NCT04491955","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5 • CD4","pipe":"","alterations":" ","tags":["CEACAM5 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-11-14"},{"id":"9d759b1e-1179-43f0-84f0-2e00510ccf08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840994","created_at":"2021-01-18T13:56:43.083Z","updated_at":"2024-07-02T16:36:49.478Z","phase":"Phase 1","brief_title":"A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02840994","lead_sponsor":"Bavarian Nordic","biomarkers":" ALK • ROS1 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression","tags":["ALK • ROS1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-02-27"},{"id":"d1de477e-4158-46d8-b4ef-18de32556c68","acronym":"","url":"https://clinicaltrials.gov/study/NCT00088413","created_at":"2021-01-18T00:15:43.686Z","updated_at":"2024-07-02T16:37:00.590Z","phase":"Phase 1/2","brief_title":"PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","source_id_and_acronym":"NCT00088413","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5","pipe":" | ","alterations":" MUC1 expression • HLA-A2 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/21/2004","start_date":" 07/21/2004","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 05/31/2018","study_completion_date":" 05/31/2018","last_update_posted":"2019-04-16"}]